JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

SHANGHAI, Sept. 26, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced updated 1-year follow-up result of relmacabtagene autoleucel injection...